We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • My watchlists
  • Help
  • Contact us

Catalyst Pharmaceutical Inc (CPRX) Com Stk USD0.001

Sell:$6.89 Buy:$6.93 Change: $0.16 (2.26%)
Market closed |  Prices as at close on 8 December 2021 | Switch to live prices |
Sell:$6.89
Buy:$6.93
Change: $0.16 (2.26%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 8 December 2021 | Switch to live prices |
Sell:$6.89
Buy:$6.93
Change: $0.16 (2.26%)
Market closed |  Prices as at close on 8 December 2021 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company. The Company is focused on in-licensing, developing, and commercializing medicines for patients living with rare diseases. The Company is developing a pipeline of medicines for other rare diseases. The Company's product Firdapse Tablet, 10 mg, is used for the treatment of adults with Lambert-Eaton Myasthenic Syndrome (LEMS) patients (ages 17 and above) in the United States and Canada. Firdapse consists of the phosphate salt of amifampridine. It is developing a long-acting formulation of amifampridine phosphate. The Company's Firdapse is also developing clinical trials for the treatment of muscle-specific receptor tyrosine kinase-positive myasthenia gravis (MuSK-MG). Catalyst Pharmaceuticals Ireland, Ltd. is the subsidiary of the Company.

Contact details

Address:
355 ALHAMBRA CIRCLE, SUITE 801
CORAL GABLES
33134
United States
Telephone:
+1 (305) 5292522
Website:
https://catalystpharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
CPRX
ISIN:
US14888U1016
Market cap:
$729.04 million
Shares in issue:
103.12 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Patrick McEnany
    Chairman of the Board, President, Chief Executive Officer
  • Alicia Grande
    Chief Financial Officer, Vice President, Treasurer
  • Steven Miller
    Chief Operating Officer, Chief Scientific Officer
  • Brian Elsbernd
    Chief Compliance Officer, Chief Legal Officer
  • Mary Coleman
    Vice President, Head of Investor Relations
  • Jeffrey Del Carmen
    Chief Commercial Officer
  • Gary Ingenito
    Chief Medical Officer and Head of Regulatory Affairs

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.